DAC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
=== Determination of concentration using a calibration curve === Standard solutions are commonly used to determine the concentration of an analyte species via calibration curve. A calibration curve is obtained by measuring a series of standard solutions with known concentrations, which can be used to determine the concentration of an unknown sample using linear regression analysis. For example, by comparing the absorbance values of a solution with an unknown concentration to a series of standard solutions with varying concentrations, the concentration of the unknown can be determined using Beer's Law. Any form of spectroscopy can be used in this way so long as the analyte species has substantial absorbance in the spectra. The standard solution is a reference guide to discover the molarity of unknown species. The matrix effect can negatively affect the efficiency of a calibration curve due to interactions between matrix and the analyte response. The matrix effect can be reduced by the addition of internal standards to the standard solutions, or by using the standard addition method.
== Sources == Abu Izzedin, Nejla M. (1993) [1984]. The Druzes: A New Study of Their History, Faith, and Society (2nd ed.). Leiden and New York: Brill. ISBN 90-04-09705-8. Aytekin, E. Attila (2012). "Peasant Protest in the Late Ottoman Empire: Moral Economy, Revolt, and the Tanzimat Reforms". International Review of Social History. 57 (2): 191–227. doi:10.1017/S0020859012000193. hdl:11511/48429. Aalund, Flemming (1992). Vernacular Tradition and the Islamic Architecture of Bosra (PDF) (PhD). Copenhagen: The Royal Academy of Fine Arts School of Architecture. Batatu, H. (1999). Syria's Peasantry, the Descendants of Its Lesser Rural Notables, and Their Politics. Princeton University Press. ISBN 0-691-00254-1. Betts, Robert Brenton (1988). The Druze. New Haven: Yale University Press. ISBN 0-300-04100-4. Burkitt, Francis C. (1925). The Religion of the Manichees: Donnellan Lectures 1924. Cambridge, England: Cambridge University Press. OCLC 79046876. Chehab, Hafez (1994). "Reconstructing the Medici Portrait of Fakhr al-Din Maʾani". Muqarnas. 11: 117–124. doi:10.2307/1523213. JSTOR 1523213. Cross, Frank L.; Livingstone, E.A., eds. (2005). Oxford Dictionary of the Christian Church. Oxford University Press. ISBN 978-0-19-280290-3. Archived from the original on May 15, 2019. Retrieved October 8, 2020. Daftary, Farhad (2007). The Ismāʿı̄lı̄s: Their History and Doctrines (Second ed.). Cambridge: Cambridge University Press. ISBN 978-0-521-61636-2. Dana, Nissi (2003). The Druze in the Middle East: Their Faith, Leadership, Identity and Status. University of Michigan Press. p. 56.
For generic manufacturers, the act created a new approval mechanism, the Abbreviated New Drug Application (ANDA), in which the generic drug manufacturer need only demonstrate that their generic formulation has the same active ingredient, route of administration, dosage form, strength, and pharmacokinetic properties ("bioequivalence") as the corresponding brand-name drug. This act has been credited with, in essence, creating the modern generic drug industry. Concerns about the length of the drug approval process were brought to the fore early in the AIDS epidemic. In the mid and late 1980s, ACT-UP and other HIV activist organizations accused the FDA of unnecessarily delaying the approval of medications to fight HIV and opportunistic infections. Partly in response to these criticisms, the FDA issued new rules to expedite approval of drugs for life-threatening diseases, and expanded pre-approval access to drugs for patients with limited treatment options. All of the initial drugs approved for the treatment of HIV/AIDS were approved through these accelerated approval mechanisms. Frank Young, then commissioner of the FDA, was behind the Action Plan Phase II, established in August 1987 for quicker approval of AIDS medication. In two instances, state governments have sought to legalize drugs that the FDA has not approved.
Sources: en.wikipedia.org
Preparing her to rule, Viserys informs Rhaenyra of their ancestor Aegon the Conqueror's dream of a supernatural threat from the north that can only be defeated if a Targaryen is on the Iron Throne, a secret prophecy known as the Song of Ice and Fire. Viserys officially declares Rhaenyra as his legal heir, and various lords across Westeros swear fealty to Rhaenyra. Six months later, Viserys denies Master of Ships Lord Corlys Velaryon and Rhaenyra's requests to pursue military action against the Triarchy, hoping to avoid war with Essos. Corlys and his wife Rhaenys propose that Viserys marry their 12-year-old daughter Laena Velaryon, while Alicent continues to chat with Viserys in private. The small council is informed that Daemon has stolen a dragon egg and taken control of Dragonstone, leading to a confrontation between Otto and Daemon that is settled by Rhaenyra persuading Daemon to return the egg. Viserys is upset with Rhaenyra for disobeying his orders, and has a deeply personal conversation regarding the prospect of his remarriage. Ultimately, Viserys announces that he will take Alicent to be his next wife, which draws the wrath of Corlys and shocks Rhaenyra, who is best friends with Alicent. Three years later, Viserys, Alicent, Rhaenyra, and various lords are celebrating the second birthday of his son, Prince Aegon Targaryen.
Most challenging was the initiation of Joints Replacement with Artificial Implants of the Hip and Knee for diseases such as Arthritis (Rheumatism). In 1980 Mendes formed the Center for Implant Surgery which gained the support of then Minister of Health, Eliezer Shostak and the Hospital director Dov Golan. The center was an ambitious project aimed at treating patients for furthering the research and development of Artificial Implants and advanced Biomaterials to upgrade them. The center was later recognized as a National Institute by Minister of Health, Shoshana Arbeli-Almozlino. Mendes organized and directed a series of annual International Orthopaedic Surgery Conventions which ran for fifteen years, attracting researchers, scientists, surgeons and medical industry entrepreneurs from around the world.
A shipping container is a container with strength suitable to withstand shipment, storage, and handling. Shipping containers range from large reusable steel boxes used for intermodal shipments to the ubiquitous corrugated boxes. In the context of international shipping trade, "container" or "shipping container" is virtually synonymous with intermodal freight container (sometimes informally called a "sea can"), a container designed to be moved from one mode of transport to another without unloading and reloading.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.